Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Joshua Brody(New York University), Raúl Córdoba(Hospital Universitario Fundación Jiménez Díaz), Kübra Karagoz(Thomas Jefferson University), Yasmin Karimi(Michigan Medicine), Malene Risum(Genmab (Denmark)), David Belada(Charles University), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Régis Costello(Inserm), Björn E. Wahlin(Karolinska University Hospital), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Marc André(CHU Dinant Godinne UCL Namur), Marek Trněný(Charles University), Liwei Wang(Shanghai First People's Hospital), Aqeel Abbas(Genmab (United States)), David Lewis(University Hospitals Plymouth NHS Trust), Tony Jiang(University of British Columbia), Umberto Vitolo(Candiolo Cancer Institute), Judit Jørgensen(Aarhus University Hospital), Andrew J. Steele(Carnegie Institution for Science)
Cited by 56
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k